Mural Oncology (NASDAQ:MURA) Downgraded to “Equal Weight” Rating by Morgan Stanley

Mural Oncology (NASDAQ:MURA) was downgraded by Morgan Stanley from an “overweight” rating to an “equal weight” rating in a research report issued to clients and investors on Tuesday,Briefing.com Automated Import reports.

Other analysts have also issued research reports about the stock. Jones Trading restated a “hold” rating on shares of Mural Oncology in a research report on Tuesday. Raymond James lowered Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price target for the company. in a research note on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Mural Oncology in a research report on Wednesday, March 12th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Mural Oncology has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Mural Oncology Trading Down 59.0 %

Shares of MURA stock traded down $2.26 during trading hours on Tuesday, hitting $1.57. The company’s stock had a trading volume of 3,112,164 shares, compared to its average volume of 157,436. The company has a 50 day moving average of $3.91 and a 200 day moving average of $3.63. The stock has a market cap of $27.07 million, a PE ratio of -0.17 and a beta of 3.66. Mural Oncology has a 12-month low of $2.87 and a 12-month high of $5.12.

Mural Oncology (NASDAQ:MURA) last issued its earnings results on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same period in the previous year, the firm posted ($3.57) earnings per share. As a group, analysts anticipate that Mural Oncology will post -7.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mural Oncology

A number of hedge funds have recently modified their holdings of MURA. Geode Capital Management LLC raised its holdings in Mural Oncology by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock valued at $595,000 after acquiring an additional 4,731 shares during the last quarter. FMR LLC increased its holdings in shares of Mural Oncology by 124.7% in the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after purchasing an additional 11,423 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Mural Oncology during the third quarter worth approximately $340,000. Commerce Bank purchased a new position in Mural Oncology during the third quarter worth approximately $39,000. Finally, Jane Street Group LLC purchased a new stake in Mural Oncology in the 4th quarter valued at $68,000. 80.21% of the stock is currently owned by institutional investors and hedge funds.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.